N/A
Completed N=6,896
Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use
Prostatic Hyperplasia
Source: ClinicalTrials.gov NCT01332435 ↗
Enrolled (actual)
6,896
Serious AEs
—
Results posted
Jul 2011
Primary outcomePrimary: Number of Participants With Clinical Progression — 176; 202; 266; 232 participants — p=<0.001
Summary
This retrospective study aims to assess the economic impact of early initiation of 5-alpha-reductase inhibitor (5ARI) therapy in patients with enlarged prostate (EP) receiving 5ARI and alpha-blocker (AB) combination therapy. Both the Integrated Health Care Information Solutions and PharMetrics databases will be utilized for this study (2000-2007).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Clinical Progression |
176; 202; 266; 232 | <0.001 sig |
| PRIMARY Number of Participants With Acute Urinary Retention |
127; 140; 182; 166 | <0.001 sig |
| PRIMARY Number of Participants Who Needed Prostate-Related Surgery |
75; 101; 130; 104 | <0.001 sig |
| SECONDARY Total BPH-related Costs |
1417; 1606; 1735; 1686 | <0.001 sig |
| SECONDARY BPH-related Medical Costs |
349; 618; 344; 449 | <0.001 sig |
| SECONDARY BPH-related Pharmacy Costs |
1068; 1417; 1392; 1237 | — |
Eligibility Criteria
Inclusion Criteria
- Male patients aged 50 years or older
- a medical claim of EP
- a prescription claim for a 5ARI and AB (provided both are within 180 days of index date)
- continuously eligible for 6 months prior to and at least 12 months after index prescription date.
Exclusion Criteria
- diagnosis of prostate or bladder cancer
- any prostate-related surgical procedure within 5 months of index date
- prescription claim for finasteride indicative of male pattern baldness
- 5ARI therapy initiated prior to initiating AB therapy
Data sourced from ClinicalTrials.gov (NCT01332435). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.